Medications denied for pain today – Celebrex, Skelaxin, Morphine, Oxycodone, Methadone, Suboxone

.

.

.

Happy New Year. Medications are denied for pain one month after you sign onto new insurance based on medications they cover:

 

Celebrex, a generic NSAID, less risk of GI bleed which is an increased in seniors day by day as we age.

 

Skelaxone, generic muscle relaxant

 

Lorzone, muscle relaxant

 

Morphine 30 mg ER, generic, denied 3 per day, well within CDC guidelines

 

Methadone 10 mg 3/day, well within CDC guidelines

 

Oxycodone 5 mg 3/day, well within CDC guidelines

 

Suboxone generic,  FDA approved for addiction in US but not for pain; approved for pain and for addiction in EU.

 

Does insurance cover cost of medication?

 

 .

.

.

.

.

.

.

.

.

.

Pain’s mill wheel – Rabindranath Tagore

.

.

.

SICKBED 5, by RABINDRANATH TAGORE  

.

November 4, 1940
.
Under this vast universe
pain’s mill wheel rotates,
grinds planets and stars to powder.
Sparks flash, scatter
suffering on every side,
ash-webs from annihilated worlds
permeating in an instant.
In the mills of oppression,
in cells of luminous consciousness,
pikes and knives clank,
wound-blood spurts.
The tiny human body—
infinite, its power to face pain.
In the assembly of creation and annihilation,
this small vessel of blood
offered to the Tantric circle
reels, drunken, rapturous.
The clay cup of the body fills
with incoherent blood, floods with tears.
Every moment unfolds unending
worth to consciousness, invincible.
The body’s pain-hallowed fire,
the offering sacrificed to ascetic acts of stars,
is incomparable.
Such enduring vigor,
compassion without fear,
indifference to death,
such triumphant processions:
assemblies trampling beds of flame
to find pain’s limits—
on a fevered, unnamed pilgrimage,
together, from path to path,
penetrating caves of fire, to find care’s origins,
provisions of unending love.

First Published in The Kenyon Review, Volume 23 #2

(Spring 2001)
http://www.kenyonreview.org/roth

.

.

.

.

.

.

.

.

.

.

.

.

.